Abstract
The traditional linear model of the RAS has now been replaced by a dynamic system than includes a number of new components. Among them the angiotensin converting enzyme type 2 has recently become recognized as an important homeostatic factor and counterbalance to ACE, modulating the balance between vasoconstrictors and vasodilators within the heart and kidney, and playing a significant role in regulating cardiovascular and renal function. However, ACE2 also has a number of important independent actions as evidence by its differential distribution in both development and in adult tissues. Studies from knockout mice suggest that ACE2 is involved in both cardiac and renal development. ACE2 is also involved in a number of disease processes, most notably ACE2 has been reported recently to be the functional receptor for the severe acute respiratory syndrome (SARS) coronavirus. A reduction in ACE2 in diabetes may also contribute to endorgan damage. ACE2 may also have important functional consequences in heart failure and pre-eclampsia. In this context, selective inhibitors of ACE2 will provide important tools for exploring the physiology and pathology of the enzyme in both heath and disease states.
Keywords: ace2, renin-angiotensin system, angiotensin II, angiotensin, hypertension, diabetes, renal impairment, sars
Current Enzyme Inhibition
Title: ACE2; an ACE up the Sleeve?
Volume: 1 Issue: 1
Author(s): M. C. Thomas and C. Tikellis
Affiliation:
Keywords: ace2, renin-angiotensin system, angiotensin II, angiotensin, hypertension, diabetes, renal impairment, sars
Abstract: The traditional linear model of the RAS has now been replaced by a dynamic system than includes a number of new components. Among them the angiotensin converting enzyme type 2 has recently become recognized as an important homeostatic factor and counterbalance to ACE, modulating the balance between vasoconstrictors and vasodilators within the heart and kidney, and playing a significant role in regulating cardiovascular and renal function. However, ACE2 also has a number of important independent actions as evidence by its differential distribution in both development and in adult tissues. Studies from knockout mice suggest that ACE2 is involved in both cardiac and renal development. ACE2 is also involved in a number of disease processes, most notably ACE2 has been reported recently to be the functional receptor for the severe acute respiratory syndrome (SARS) coronavirus. A reduction in ACE2 in diabetes may also contribute to endorgan damage. ACE2 may also have important functional consequences in heart failure and pre-eclampsia. In this context, selective inhibitors of ACE2 will provide important tools for exploring the physiology and pathology of the enzyme in both heath and disease states.
Export Options
About this article
Cite this article as:
Thomas C. M. and Tikellis C., ACE2; an ACE up the Sleeve?, Current Enzyme Inhibition 2005; 1 (1) . https://dx.doi.org/10.2174/1573408052952739
DOI https://dx.doi.org/10.2174/1573408052952739 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effect of Dietary Education on Cardiovascular Risk Factors in Rheumatoid Arthritis Patients
Current Rheumatology Reviews Effects of Antiplatelet Medication on Arteriovenous Fistula Patency After Surgical Thrombectomy
Current Vascular Pharmacology Evaluation of the Possible Contribution of Antioxidants Administration in Metabolic Syndrome
Current Pharmaceutical Design HIV-1 Vectors: Fulfillment of Expectations, Further Advancements, and Still A Way To Go
Current HIV Research Discovery and Development of Purine-Scaffold Hsp90 Inhibitors
Current Topics in Medicinal Chemistry Cilostazol: A New Drug in the Treatment Intermittent Claudication
Recent Patents on Cardiovascular Drug Discovery Effect of β-Blockers on Perioperative Myocardial Ischemia in Patients Undergoing Noncardiac Surgery
Current Drug Targets Current Status of Therapeutic Angiogenesis with Protein, Gene and Cell Therapy
Current Drug Therapy The Pathway Less Traveled: Moving from Candidate Genes to Candidate Pathways in the Analysis of Genome-Wide Data from Large Scale Pharmacogenetic Association Studies
Current Pharmacogenomics and Personalized Medicine Benzofuran Small Molecules as Potential Inhibitors of Human Protein Kinases. A Review
Current Pharmaceutical Design What is Tobacco Smoke? Sociocultural Dimensions of the Association with Cardiovascular Risk
Current Pharmaceutical Design Pharmacotherapy Before and After Endovascular Repair of Abdominal Aortic Aneurysms
Current Vascular Pharmacology The Role of Antithrombotic Therapy in Heart Failure
Current Pharmaceutical Design Pleiotropic, Cardioprotective Effects of Omega-3 Polyunsaturated Fatty Acids
Mini-Reviews in Medicinal Chemistry Endogenous Ligand Bias by Chemokines: Implications at the Front Lines of Infection and Leukocyte Trafficking
Endocrine, Metabolic & Immune Disorders - Drug Targets Cardiovascular Effects of Current and Future Anti-Obesity Drugs
Current Vascular Pharmacology Novel Therapeutic Strategies Targeting Vascular Redox in Human Atherosclerosis
Recent Patents on Cardiovascular Drug Discovery Protective and Therapeutic Effects of Ghrelin in the Gut
Current Medicinal Chemistry Non-Vitamin K Oral Anticoagulants (NOACs) A Review of Clinical Management and Laboratory Issues
Current Vascular Pharmacology Systems Biology and Biomechanical Model of Heart Failure
Current Cardiology Reviews